论文部分内容阅读
目的:探讨奥拉西坦联合依达拉奉对急性脑梗死的疗效以及安全性。方法:对我院收治的132例急性脑梗死患者随机分为实验组以及对照组,实验组患者采用奥拉西坦联合依达拉奉进行治疗,对照组患者采用依达拉奉进行治疗,对两组患者治疗前后NIHSS评分、Barthel指数、临床疗效以及脑梗死面积进行比较。结果:实验组患者在接受治疗2周期NIHSS评分、Barthel指数明显优于对照组(P<0.05);实验组患者其治疗痊愈以及显效例数为55例以及9例明显优于对照组的8例以及8例(P<0.05);实验组患者接受治疗后其梗死面积为7.21±4.32cm2,明显优于对照组的14.32±5.49 cm2。结论:对于急性脑梗死患者采用奥拉西坦联合依达拉奉进行治疗,可有效改善患者预后,降低伤残率,改善患者预后。
Objective: To investigate the efficacy and safety of oxiracetam combined with edaravone in patients with acute cerebral infarction. Methods: 132 cases of acute cerebral infarction admitted to our hospital were randomly divided into experimental group and control group. Patients in experimental group were treated with oxiracetam combined with edaravone, while those in control group were treated with edaravone. The NIHSS score, Barthel index, clinical efficacy and infarct size were compared between the two groups before and after treatment. Results: The NIHSS score and Barthel index of the experimental group were significantly better than those of the control group (P <0.05). The experimental group was cured and the number of effective cases was 55 and 9 cases were significantly better than the control group (P <0.05). The area of infarction in experimental group was 7.21 ± 4.32cm2, which was significantly better than that of control group (14.32 ± 5.49cm2). Conclusion: The treatment of patients with acute cerebral infarction with oxiracetam combined with edaravone can effectively improve the prognosis of patients, reduce the disability rate and improve the prognosis of patients.